FOLH1 and prostate cancer: Salivary glands as the primary dose-limiting organ: an integrated dosimetry, efficacy, and toxicity study of &lt;sup&gt;225&lt;/sup&gt;Ac-PSMA-617 in prostate cancer xenografts.